FDA Guidance for Industry
Supplemental Guidance on Testing for Replication Competent Retrovirus in Retroviral Vector Based Gene Therapy Products and During
Follow-up of Patients in Clinical
Trials Using Retroviral Vectors
Titel:
FDA Guidance for Industry
Supplemental Guidance on Testing for Replication Competent Retrovirus in Retroviral Vector Based Gene Therapy Products and During
Follow-up of Patients in Clinical
Trials Using Retroviral Vectors
Cookies helfen uns bei der Bereitstellung unserer Dienste. Durch die Nutzung unserer Dienste erklären Sie sich damit einverstanden, dass wir Cookies setzen. Weitere Informationen